T Cell Manufacturing with PI3K Inhibitor
Solution Overview
Problem
Current methods for generating therapeutic doses of T cells for adoptive immunotherapy are limited by cumbersome manufacturing processes, leading to short-lived effects and lack of persistence and expansion of T cells in vivo.
Innovation Solution
An ex vivo or in vitro method for manufacturing T cells involving activation, stimulation, and transduction with a viral vector encoding an anti-BCMA chimeric antigen receptor (CAR), performed in the presence of a PI3K inhibitor to maintain proliferation and reduce differentiation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If T cells are activated and expanded using conventional methods to achieve therapeutic doses, then T cell numbers increase, but T cell differentiation increases and persistence in vivo decreases
Solution Approach 1:
The patent changes the chemical parameter of the culture medium by adding a PI3K inhibitor (such as IC87114 or Wortmannin) to block the PI3K signaling pathway. This parameter change uncouples T cell proliferation from differentiation, allowing expansion of T cells while maintaining their undifferentiated, persistent state. The inhibitor concentration is optimized to achieve therapeutic T cell numbers without inducing exhaustion markers.
2Quantity of substance
If multiple rounds of activation and expansion are performed to generate therapeutic T cell doses, then T cell numbers increase, but manufacturing complexity and time increase
Solution Approach 1:
The patent applies preliminary action by pre-treating T cells with PI3K inhibitors before and during the activation and expansion process. This preliminary intervention prevents differentiation from occurring during expansion, eliminating the need for multiple sequential activation rounds that are typically required to generate sufficient therapeutic doses. The process achieves high T cell numbers in a single expansion phase.
3Quantity of substance
If T cells are extensively activated and expanded in vitro, then therapeutic doses are achieved, but T cell exhaustion and loss of effector function increase
Solution Approach 1:
The patent extracts or blocks the specific PI3K signaling pathway using pharmacological inhibitors while allowing other T cell activation and expansion pathways to proceed normally. This selective intervention prevents the differentiation and exhaustion programs that are normally triggered by extensive activation, thereby maintaining T cell effector function and persistence capabilities while still achieving therapeutic expansion.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method results in T cells with improved survival, expansion, and persistence in vivo, maintaining proliferation and decreasing differentiation compared to T cells activated without a PI3K inhibitor.
Implementation Method 1
treating a population of cells comprising T cells with an inhibitor of a PI3K/AKT/mTOR pathway
Implementation Method 2
modifying the T cells to express one or more proteins of interest
Data Source
Figure 1a~1b
Figure 2a~2b
Figure 3
AI summary
The invention provides improved T cell compositions and methods for manufacturing T cells. More particularly, the invention provides methods of T cell manufacturing that result in adoptive T cell immunotherapies with improved survival, expansion, and persistence in vivo.